Answers are grounded in this paper and cite their sources.
Background/Objectives: Autism spectrum disorder (ASD) lacks pharmacological therapies for its core features. This study synthesized chalcone derivatives, determined their monoamine oxidase A (MAO-A) and MAO-B inhibitory profiles, and generated computational hypotheses regarding MAO-B binding, gut–bacterial protein interactions, and drug-like properties. Methods: Sixteen chalcones (23–38; fifteen newly reported) were synthesized and characterized. MAO-A and MAO-B inhibition was measured using fluorometric concentration–response assays, with clorgyline and safinamide as references. Compounds 23, 26, 35, and 37 were docked against human MAO-B (PDB 2V5Z), Bacteroides fragilis profragilysin-3 (PDB 7POU), and Lacticaseibacillus casei thymidylate synthase (PDB 1LCA and 3IK1), and subjected to in silico ADMET assessment. Results: Compound 37 showed the best balance of MAO-B potency and selectivity, with an IC50 of 0.636 µM and a selectivity index of 16.65. Compound 35 was also MAO-B-selective (IC50 = 2.52 µM; selectivity index = 13.24). Compound 34 was the most potent dual inhibitor (MAO-A IC50 = 0.647 µM; MAO-B IC50 = 0.272 µM), whereas none met the predefined MAO-A-selectivity threshold. Docking suggested accommodation of the chalcones within the MAO-B cavity, the peripheral hesperetin-binding pocket of profragilysin-3, and the thymidylate-synthase folate/dUMP cleft. Predicted ADMET profiles indicated limited absorption, extensive protein binding, and potential hepatic and genotoxic liabilities. Conclusions: Compound 37 is the leading selective MAO-B scaffold, while compound 35 provides a second selective chemotype. The bacterial-target docking and ADMET findings are hypothesis-generating only and do not demonstrate effects on toxin activity, bacterial growth, microbiome composition, safety, central exposure, or ASD-related outcomes. Enzyme kinetics, target-engagement, permeability, genotoxicity, and microbiological studies are required before in vivo evaluation.
No takes yet. Share an insight, caveat, or question.
Aqeel et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: